Danaher (NYSE:DHR) issued an update on its FY 2018 earnings guidance on Thursday morning. The company provided earnings per share guidance of $4.49-4.52 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.49. Danaher also updated its FY18 guidance to $4.49-4.52 EPS.
DHR stock traded down $0.36 on Friday, hitting $104.39. The company had a trading volume of 2,608,564 shares, compared to its average volume of 3,078,206. Danaher has a 12-month low of $91.65 and a 12-month high of $110.13. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $72.94 billion, a P/E ratio of 25.90, a P/E/G ratio of 2.00 and a beta of 1.04.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, October 18th. The conglomerate reported $1.10 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.07 by $0.03. Danaher had a net margin of 14.07% and a return on equity of 11.59%. The company had revenue of $4.85 billion for the quarter, compared to analysts’ expectations of $4.80 billion. During the same quarter last year, the company posted $1.00 earnings per share. The firm’s quarterly revenue was up 7.2% on a year-over-year basis. As a group, equities analysts predict that Danaher will post 4.51 earnings per share for the current year.
Several brokerages have recently weighed in on DHR. Zacks Investment Research cut shares of Danaher from a hold rating to a sell rating in a research note on Monday, July 16th. Royal Bank of Canada lifted their price target on shares of Danaher to $107.00 and gave the stock a positive rating in a research note on Thursday, July 19th. They noted that the move was a valuation call. Morgan Stanley lifted their price target on shares of Danaher from $120.00 to $122.00 and gave the stock an overweight rating in a research note on Friday, July 20th. Bank of America set a $113.00 price target on shares of Danaher and gave the stock a buy rating in a research note on Thursday, July 19th. Finally, Robert W. Baird dropped their price target on shares of Danaher from $116.00 to $114.00 and set an outperform rating on the stock in a research note on Friday, October 19th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Danaher currently has an average rating of Buy and an average price target of $112.14.
In other Danaher news, insider Thomas Patrick Joyce, Jr. sold 5,212 shares of Danaher stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $103.89, for a total value of $541,474.68. Following the sale, the insider now directly owns 151,829 shares in the company, valued at approximately $15,773,514.81. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Donald J. Ehrlich sold 10,578 shares of the business’s stock in a transaction dated Tuesday, October 23rd. The stock was sold at an average price of $95.77, for a total transaction of $1,013,055.06. Following the completion of the sale, the director now owns 105,491 shares in the company, valued at $10,102,873.07. The disclosure for this sale can be found here. Insiders have sold a total of 150,007 shares of company stock worth $15,202,163 over the last 90 days. Insiders own 11.90% of the company’s stock.
WARNING: “Danaher (NYSE:DHR) Issues FY 2018 Earnings Guidance” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/11/10/danaher-dhr-issues-fy-2018-earnings-guidance/2847420.html.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Featured Story: Ex-Dividend
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.